Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 monoclonal antibody plus interferon-gamma with chemotherapy for pancreatic cancer
ChiCTR1800017665Phase 4Recruiting
- Sponsor
- Huzhou Central Hospital
- Start
- Nov 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of PD-1 Monoclonal Antibody and interferon gamma-1b in pancreatic cancer (PC) (2 arms), sponsored by Huzhou Central Hospital. Primary endpoints: Incidence of complications, Tumor-free survival time and 5 more. Started Nov 2018; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibodyinterferon gamma-1b
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR1800017665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017665.